VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Amanda J Hooper^{1

2}, Xuan L Tang¹, John R Burnett^{1

2}

Affiliations

¹ Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.
² School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Editorial

Amanda J Hooper et al. Expert Opin Investig Drugs. 2024 Aug.

. 2024 Aug;33(8):753-756.

doi: 10.1080/13543784.2024.2369747. Epub 2024 Jun 21.

Amanda J Hooper^{1

2}, Xuan L Tang¹, John R Burnett^{1

2}

¹ Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.
² School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

No abstract available

Keywords: Base editing; CRISPR; LDL; LDL-cholesterol; PCSK9; PCSK9 inhibitor; VERVE-101; VERVE-102.

Publication types